| | GLA, RPL36A-HNRNPH2 (W399S) | Single nucleotide variant (missense variant +2 more) | Fabry disease +4 more | |
| | GLA, RPL36A-HNRNPH2 (R392S) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GLikely pathogenic; drug response |
| | GLA, RPL36A-HNRNPH2 (G375A) | Single nucleotide variant (missense variant +2 more) | Fabry disease | |
| | GLA, RPL36A-HNRNPH2 (R356P) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GPathogenic; drug response |
| | RPL36A-HNRNPH2, GLA (A352G) | Single nucleotide variant (missense variant +2 more) | not provided +2 more | GConflicting classifications of pathogenicity |
| | GLA, RPL36A-HNRNPH2 (Q330R) | Single nucleotide variant (missense variant +2 more) | Fabry disease | |
| | GLA, RPL36A-HNRNPH2 (Q327L) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GPathogenic; drug response |
| | GLA, RPL36A-HNRNPH2 (Q327R) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GPathogenic; drug response |
| | GLA, RPL36A-HNRNPH2 (P323R) | Single nucleotide variant (missense variant +2 more) | Fabry disease | |
| | GLA, RPL36A-HNRNPH2 (I317S) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GPathogenic; drug response |
| | GLA, RPL36A-HNRNPH2 (V316A) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | |
| | GLA, RPL36A-HNRNPH2 (D315N) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GUncertain significance; drug response |
| | GLA, RPL36A-HNRNPH2 (D313N) | Single nucleotide variant (missense variant +2 more) | Fabry disease +2 more | GConflicting classifications of pathogenicity |
| | GLA, RPL36A-HNRNPH2 (A309V) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | |
| | GLA, RPL36A-HNRNPH2 (I289V) | Single nucleotide variant (missense variant +2 more) | Fabry disease +3 more | GConflicting classifications of pathogenicity |
| | GLA, RPL36A-HNRNPH2 (V269G) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GPathogenic; drug response |
| | GLA, RPL36A-HNRNPH2 (W262R) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GPathogenic; drug response |
| | GLA, RPL36A-HNRNPH2 (V254A) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GLikely pathogenic; drug response |
| | GLA, RPL36A-HNRNPH2 (I242V) | Single nucleotide variant (missense variant +2 more) | Fabry disease +2 more | |
| | GLA, RPL36A-HNRNPH2 (N228S) | Single nucleotide variant (missense variant +2 more) | Fabry disease | |
| | GLA, RPL36A-HNRNPH2 (R227P) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GPathogenic; drug response |
| | GLA, RPL36A-HNRNPH2 (I219M) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GLikely pathogenic; drug response |
| | GLA, RPL36A-HNRNPH2 (P214L) | Single nucleotide variant (missense variant +2 more) | Fabry disease | |
| | GLA, RPL36A-HNRNPH2 (K213R) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GPathogenic; drug response |
| | GLA, RPL36A-HNRNPH2 (W204R) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | |
| | GLA, RPL36A-HNRNPH2 (R196S) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GUncertain significance; drug response |
| | GLA, RPL36A-HNRNPH2 (M187I) | Single nucleotide variant (intron variant +2 more) | Fabry disease +1 more | GPathogenic; drug response |
| | GLA, RPL36A-HNRNPH2 (L180F) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GConflicting classifications of pathogenicity |
| | GLA, RPL36A-HNRNPH2 (V164L) | Single nucleotide variant (missense variant +2 more) | Fabry disease | |
| | GLA, RPL36A-HNRNPH2 (I154T) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GUncertain significance; drug response |
| | GLA, RPL36A-HNRNPH2 (A121T) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | |
| | GLA, RPL36A-HNRNPH2 (F113I) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GLikely pathogenic; drug response |
| | GLA, RPL36A-HNRNPH2 (I91N) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GPathogenic; drug response |
| | GLA, RPL36A-HNRNPH2 (Y86H) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GPathogenic; drug response |
| | GLA, RPL36A-HNRNPH2 (G80D) | Single nucleotide variant (intron variant +2 more) | not specified +3 more | GConflicting classifications of pathogenicity |
| | GLA, RPL36A-HNRNPH2 (E71G) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | |
| | GLA, RPL36A-HNRNPH2 (I64F) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GPathogenic; drug response |
| | GLA, RPL36A-HNRNPH2 (L36W) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GPathogenic; drug response |
| | GLA, RPL36A-HNRNPH2 (G35E) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GPathogenic; drug response |
| | GLA, RPL36A-HNRNPH2 (D33G) | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GPathogenic; drug response |
| | RPL36A-HNRNPH2, GLA (L21P) | Single nucleotide variant (missense variant +2 more) | Fabry disease | |
| | RPL36A-HNRNPH2, GLA (A20D) | Single nucleotide variant (missense variant +2 more) | Fabry disease | GPathogenic/Likely pathogenic |
| | | Single nucleotide variant (missense variant +2 more) | Fabry disease +1 more | GUncertain significance; drug response |
| | GLA, RPL36A-HNRNPH2 (I253T) | Single nucleotide variant (missense variant +2 more) | not provided +2 more | GConflicting classifications of pathogenicity |
| | | Single nucleotide variant (missense variant +2 more) | Cardiovascular phenotype +2 more | GConflicting classifications of pathogenicity |
| | | Single nucleotide variant (missense variant +2 more) | Fabry disease +3 more | GConflicting classifications of pathogenicity |